Clinical Laboratory in Arizona

ZINGO Digital Dental Lab LLC (doing business as Digital Dental) is a Scottsdale, Arizona-based dental technology manufacturer established in 1977. The company specializes in advanced CAD/CAM milling machines, high-performance dental materials (zirconia, PMMA, nanoceramics), and comprehensive laboratory services for dental labs and practitioners. Digital Dental introduced the first open-architecture, industrial-strength dental milling machine in 2006, designed for high-production environments. The company manufactures custom abutment mills, automated aligner trimming machines, pre-fabricated abutment blanks, and hybrid denture solutions. With an FDA-registered Milling Center, Digital Dental offers outsourced milling services, custom abutments, crowns, and full-arch restorations. The company emphasizes American manufacturing and support, with over 98% of machines actively in use. Digital Dental serves dental laboratories and dentists with integrated mill systems, quality management platforms, and large inventory availability to reduce waste and improve workflow efficiency in high-volume restorative practices.

Caris Life Sciences is a precision medicine and AI-driven TechBio company founded in 2008, headquartered in Phoenix, Arizona. The company specializes in molecular profiling and oncology diagnostics, operating a CLIA-certified laboratory that has processed over 1 million cases and 6.5 million tests. Caris develops comprehensive genomic and transcriptomic assays combining whole exome sequencing (WES), whole transcriptome sequencing (WTS), and protein analysis across 23,000+ genes. The company offers two primary clinical offerings: Caris Assure, a blood-based liquid biopsy utilizing circulating nucleic acid sequencing (cNAS) for pan-cancer profiling, and Caris MI Profile, a tissue-based assay delivering DNA, RNA, and protein analysis with AI-predictive algorithms. Caris maintains one of the largest multimodal databases globally—over 740,000 matched molecular and clinical outcomes records—which powers its proprietary Molecular AI platform. This AI engine generates 220+ interpretations and has measured over 50 billion molecular markers. The company serves oncologists, cancer patients, and biopharma partners across the care continuum: disease detection, therapy selection, and treatment monitoring. Caris publishes extensively (1,200+ peer-reviewed publications) and maintains partnerships with 45+ NCI-Designated Cancer Centers and 95+ members worldwide. The platform enables personalized, precision-oncology treatment decisions by revealing molecular blueprints and predicting individual patient response to therapies.